GKB Ophthalmics (BSE 533212)₹66.09−4.85%Medical Equipment & Supplies
In the Jun 2026 quarter (consolidated), GKB Ophthalmics reported sales of ₹33.02 Cr, up 2.3% from Jun 2025, and net profit of ₹1.86 Cr. For the year to Mar 2026, sales were ₹149 Cr and net profit ₹3.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.41 | 24.03 | 21.55 | 26.00 | 26.12 | 25.81 | 30.99 | 32.29 | 30.15 | 56.82 | 29.81 | 33.02 |
| Expenses | 20.63 | 24.57 | 21.48 | 24.88 | 26.12 | 26.66 | 33.79 | 31.40 | 27.07 | 54.91 | 26.61 | 30.31 |
| Operating Profit | −0.28 | −0.61 | 0.00 | 1.03 | −0.05 | −0.93 | −2.85 | 0.79 | 3.01 | 1.65 | 3.07 | 2.62 |
| OPM % | −1.4% | −2.6% | 0.0% | 4.0% | −0.2% | −3.6% | −9.2% | 2.5% | 10.1% | 2.9% | 10.4% | 8.0% |
| Other Income | 0.30 | 0.34 | 0.59 | 0.27 | 0.27 | 0.47 | 0.34 | 0.22 | 0.36 | 0.56 | −0.67 | 0.74 |
| Interest | 0.45 | 0.43 | 0.56 | 0.54 | 0.54 | 0.62 | 0.62 | 0.76 | 0.65 | 0.72 | 0.51 | 0.50 |
| Depreciation | 0.72 | 0.72 | 0.71 | 0.75 | 0.76 | 0.76 | 0.79 | 0.79 | 0.81 | 0.81 | 0.79 | 0.79 |
| Profit before tax | −1.18 | −1.45 | −0.70 | 0.02 | −1.11 | −1.87 | −3.95 | −0.57 | 1.92 | 0.69 | 1.09 | 2.06 |
| Tax % | 0.0% | 0.0% | 30.4% | 600.0% | 5.4% | 2.7% | 4.8% | 14.3% | 3.7% | −4.4% | −3.7% | 9.7% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −0.99 | 0.00 |
| Net Profit | −1.20 | −1.45 | −0.90 | 0.12 | −1.16 | −1.92 | −4.14 | −0.65 | 1.85 | 0.71 | 1.13 | 1.86 |
| EPS (Rs) | −2.31 | −2.47 | −1.80 | −0.49 | −2.41 | −4.02 | −7.02 | −2.01 | 3.16 | 0.86 | 0.37 | 1.99 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 44.01 | 75.97 | 77.99 | 56.98 | 58.95 | 56.99 | 70.96 | 74.97 | 87.95 | 109 | 149 | 150 |
| Expenses | 43.84 | 74.80 | 76.72 | 55.82 | 55.78 | 54.78 | 65.79 | 71.77 | 87.69 | 112 | 139 | 139 |
| Operating Profit | −0.99 | 1.99 | 0.99 | 0.99 | 1.99 | 1.99 | 4.98 | 3.99 | 0.99 | −2.99 | 8.97 | 10.35 |
| OPM % | −1.6% | 2.5% | 1.7% | 2.0% | 3.6% | 4.0% | 7.1% | 4.9% | 0.6% | −2.5% | 6.0% | 6.9% |
| Other Income | 11.99 | 3.99 | 0.00 | 1.99 | 1.01 | 1.99 | 0.99 | 1.01 | 1.99 | 1.99 | 0.00 | 0.99 |
| Interest | 1.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 1.99 | 1.99 | 1.99 | 2.99 | 2.38 |
| Depreciation | 0.99 | 0.99 | 1.99 | 3.99 | 3.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 3.20 |
| Profit before tax | 8.01 | 3.01 | −1.01 | −2.01 | −2.01 | −1.01 | 2.01 | 0.00 | −3.01 | −7.01 | 3.01 | 5.76 |
| Tax % | 50.0% | 12.0% | −15.0% | −30.0% | 0.0% | −19.0% | 0.0% | 14.0% | 8.0% | 5.0% | 2.0% | — |
| Exceptional items | 5.99 | 1.99 | 0.00 | 0.99 | 0.00 | −0.99 | 0.00 | 0.00 | 0.00 | 0.00 | −1.99 | −0.99 |
| Net Profit | 4.02 | 3.01 | −1.01 | −1.01 | −2.01 | −1.01 | 2.01 | 0.00 | −3.01 | −7.02 | 3.01 | 5.55 |
| EPS (Rs) | 9.50 | 6.23 | −2.33 | −2.36 | −3.64 | −1.80 | 2.51 | −0.33 | −5.56 | −13.94 | 2.21 | 6.38 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.01 | 4.01 | 4.01 | 4.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 |
| Reserves | 35.91 | 40.92 | 42.89 | 40.89 | 49.86 | 53.85 | 57.90 | 57.84 | 57.87 | 54.86 | 46.88 | 47.90 |
| Borrowings | 9.03 | 7.02 | 7.02 | 10.04 | 14.05 | 15.04 | 12.03 | 12.03 | 11.03 | 11.04 | 14.04 | 12.03 |
| Other Liabilities | 25.99 | 16.98 | 27.96 | 27.96 | 24.94 | 27.98 | 31.95 | 34.93 | 37.93 | 42.97 | 58.96 | 67.82 |
| Total Liabilities | 74.94 | 68.93 | 81.88 | 82.90 | 93.86 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Fixed Assets | 11.99 | 13.01 | 17.99 | 18.01 | 26.01 | 25.99 | 24.01 | 22.99 | 18.99 | 17.99 | 17.01 | 14.99 |
| CWIP | 0.99 | 0.99 | 0.99 | 0.00 | 0.00 | 0.00 | 0.99 | 2.99 | 3.99 | 3.99 | 3.99 | 3.99 |
| Investments | 16.02 | 10.02 | 3.01 | 0.00 | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 |
| Other Assets | 45.94 | 45.91 | 59.89 | 63.89 | 67.84 | 74.88 | 79.88 | 81.82 | 86.85 | 90.89 | 102 | 111 |
| Inventories | 20.91 | 20.92 | 30.88 | 31.91 | 27.89 | 30.88 | 34.86 | 37.85 | 38.85 | 39.88 | 49.82 | 54.79 |
| Trade receivables | 17.98 | 16.98 | 24.97 | 26.97 | 23.96 | 24.96 | 18.97 | 19.97 | 27.97 | 27.95 | 24.96 | 44.97 |
| Cash & equivalents | 3.01 | 4.01 | 3.01 | 3.01 | 10.01 | 14.02 | 17.04 | 16.02 | 14.03 | 18.02 | 14.03 | 5.01 |
| Total Assets | 74.94 | 68.93 | 81.88 | 82.90 | 93.86 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 7.03 | −11.05 | −3.01 | −3.01 | 4.02 | 3.01 | 7.03 | 5.02 | −3.01 | 4.01 | −3.01 | −4.01 |
| Cash from investing activity | 0.00 | 14.96 | 3.99 | 0.99 | −9.97 | −3.99 | −16.96 | −3.99 | 0.99 | −1.99 | 2.99 | 8.98 |
| Cash from financing activity | −5.99 | −2.99 | −0.99 | 0.99 | 12.97 | 3.99 | 2.99 | −1.99 | −1.99 | −1.99 | 0.99 | −5.99 |
| Net cash flow | 1.01 | 0.00 | −0.99 | 0.00 | 7.01 | 4.01 | −6.99 | 0.00 | −4.01 | 1.01 | 0.00 | 0.00 |
| Capex | 0.67 | 3.17 | 6.34 | 1.89 | 13.22 | 3.87 | 6.34 | 4.77 | 1.22 | 2.09 | 2.16 | 1.04 |
| Free cash flow | 7.01 | −12.99 | −9.01 | −4.99 | −6.01 | 0.00 | 0.99 | 0.00 | −1.99 | 2.01 | −5.99 | −5.01 |
| CFO / OP % | 1,117.0% | 639.0% | −112.1% | −190.1% | 345.9% | 153.9% | 300.0% | 104.9% | −71.1% | 865.0% | 117.9% | −41.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 191 | 143 | 118 | 129 | 150 | 155 | 125 | 100 | 134 | 117 | 85 | 110 |
| Inventory days | 424 | 285 | 225 | 223 | 289 | 301 | 349 | 307 | 298 | 245 | 250 | 189 |
| Days payable | 343 | 156 | 169 | 168 | 217 | 234 | 234 | 208 | 183 | 202 | 195 | 195 |
| Cash conversion cycle | 270 | 271 | 173 | 183 | 221 | 222 | 238 | 198 | 248 | 159 | 140 | 103 |
| Working capital days | 97 | 156 | 111 | 115 | 110 | 110 | 117 | 105 | 135 | 97 | 78 | 78 |
| ROCE % | 0.0% | −1.0% | 3.0% | 0.0% | −2.0% | −1.0% | 3.0% | 4.0% | 2.0% | −1.0% | −6.0% | 11.0% |
For the Jun 2026 quarter, GKB Ophthalmics reported sales of ₹33.02 Cr, up 2.3% year on year and net profit of ₹1.86 Cr. The operating margin was 8.0%.
GKB Ophthalmics' sales for the year to Mar 2026 were ₹149 Cr; over the last twelve months they were ₹150 Cr.
Net profit for the year to Mar 2026 was ₹3.01 Cr, and ₹5.55 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.38.
GKB Ophthalmics reported borrowings of ₹12.03 Cr at Mar 2026, against cash and equivalents of ₹5.01 Cr.
Cash from operations was −₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹5.01 Cr.